JP3952369B2 - 新規な置換インドリノン類、その製造及びその薬剤としての使用 - Google Patents

新規な置換インドリノン類、その製造及びその薬剤としての使用 Download PDF

Info

Publication number
JP3952369B2
JP3952369B2 JP2001519696A JP2001519696A JP3952369B2 JP 3952369 B2 JP3952369 B2 JP 3952369B2 JP 2001519696 A JP2001519696 A JP 2001519696A JP 2001519696 A JP2001519696 A JP 2001519696A JP 3952369 B2 JP3952369 B2 JP 3952369B2
Authority
JP
Japan
Prior art keywords
group
alkyl
phenyl
indolinone
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001519696A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003508394A (ja
JP2003508394A5 (cg-RX-API-DMAC7.html
Inventor
ゲラルト ユルゲン ロート
アルミン ヘッケル
ライナー ヴァルター
グルント ウルリケ トンチュ
ヴァルター シュペファーク
メール ヤコブス ツェー アー ファン
Original Assignee
ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999140829 external-priority patent/DE19940829A1/de
Priority claimed from DE2000129285 external-priority patent/DE10029285A1/de
Application filed by ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト filed Critical ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト
Publication of JP2003508394A publication Critical patent/JP2003508394A/ja
Publication of JP2003508394A5 publication Critical patent/JP2003508394A5/ja
Application granted granted Critical
Publication of JP3952369B2 publication Critical patent/JP3952369B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • General Health & Medical Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Structural Engineering (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
JP2001519696A 1999-08-27 2000-08-22 新規な置換インドリノン類、その製造及びその薬剤としての使用 Expired - Fee Related JP3952369B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE1999140829 DE19940829A1 (de) 1999-08-27 1999-08-27 Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19940829.7 1999-08-27
DE2000129285 DE10029285A1 (de) 2000-06-14 2000-06-14 Neue substituierte Indolinone,ihre Herstellung und ihre Verwendung als Arzneimittel
DE10029285.2 2000-06-14
PCT/EP2000/008149 WO2001016130A1 (de) 1999-08-27 2000-08-22 Substituierte indolinone als tyrosinkinase inhibitoren

Publications (3)

Publication Number Publication Date
JP2003508394A JP2003508394A (ja) 2003-03-04
JP2003508394A5 JP2003508394A5 (cg-RX-API-DMAC7.html) 2006-12-21
JP3952369B2 true JP3952369B2 (ja) 2007-08-01

Family

ID=26006075

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001519696A Expired - Fee Related JP3952369B2 (ja) 1999-08-27 2000-08-22 新規な置換インドリノン類、その製造及びその薬剤としての使用

Country Status (12)

Country Link
US (2) US6794395B1 (cg-RX-API-DMAC7.html)
EP (1) EP1212318B1 (cg-RX-API-DMAC7.html)
JP (1) JP3952369B2 (cg-RX-API-DMAC7.html)
AR (1) AR025389A1 (cg-RX-API-DMAC7.html)
AT (1) ATE316527T1 (cg-RX-API-DMAC7.html)
AU (1) AU6998000A (cg-RX-API-DMAC7.html)
CA (1) CA2381821A1 (cg-RX-API-DMAC7.html)
CO (1) CO5180641A1 (cg-RX-API-DMAC7.html)
DE (1) DE50012136D1 (cg-RX-API-DMAC7.html)
ES (1) ES2257313T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA02002097A (cg-RX-API-DMAC7.html)
WO (1) WO2001016130A1 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10054019A1 (de) * 2000-11-01 2002-05-23 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US6638965B2 (en) * 2000-11-01 2003-10-28 Boehringer Ingelheim Pharma Kg Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
DE10117204A1 (de) 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
ES2274993T3 (es) 2001-06-29 2007-06-01 Ab Science Utilizacion de inhibidores de tirosina cinasa para el tratamiento de enfermedades alergicas.
WO2003003006A2 (en) 2001-06-29 2003-01-09 Ab Science New potent, selective and non toxic c-kit inhibitors
ATE330608T1 (de) 2001-06-29 2006-07-15 Ab Science Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen
PT1401416E (pt) 2001-06-29 2007-02-28 Ab Science Utilização de inibidores de c-kit para tratar doenças inflamatórias intestinais (dii)
US20030225152A1 (en) * 2001-09-27 2003-12-04 Andrews Steven W. 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
DE60205776T2 (de) 2001-12-27 2006-06-14 Theravance Inc Indolinon-derivative als protein-kinasehemmer
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
US7514468B2 (en) 2002-07-23 2009-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
US20040204458A1 (en) * 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
US7148249B2 (en) 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
JP4879492B2 (ja) * 2002-11-27 2012-02-22 アラーガン、インコーポレイテッド 疾患の治療のためのキナーゼ阻害剤
AU2004298448B2 (en) 2003-12-18 2010-09-09 Janssen Pharmaceutica N.V. Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents
PE20060664A1 (es) * 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
KR20080007645A (ko) * 2005-04-28 2008-01-22 베링거 인겔하임 인터내셔날 게엠베하 염증성 질환 치료용 신규 화합물
ES2348099T3 (es) * 2005-06-10 2010-11-30 Merck Patent Gmbh Oxindoles como inhibidores de cinasa.
GT200600411A (es) * 2005-09-13 2007-05-21 Novartis Ag Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
JP2009533480A (ja) * 2006-04-24 2009-09-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 3−(アミノメチリデン)2−インドリノン誘導体及びその細胞増殖抑制薬としての使用
CA2654583C (en) * 2006-07-13 2015-11-24 Janssen Pharmaceutica N.V. Mtki quinazoline derivatives
CA2690569A1 (en) * 2007-06-12 2008-12-18 Boehringer Ingelheim International Gmbh Indolinone derivatives and their use in treating disease-states such as cancer
EP2170827B1 (en) * 2007-06-21 2013-08-14 Janssen Pharmaceutica, N.V. Indolin-2-ones and aza-indolin-2-ones
AU2008281849B2 (en) 2007-07-27 2013-11-28 Janssen Pharmaceutica Nv Pyrrolopyrimidines
AU2009275964A1 (en) * 2008-07-29 2010-02-04 Boehringer Ingelheim International Gmbh New compounds
WO2014086102A1 (zh) * 2012-12-06 2014-06-12 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的吲哚满酮衍生物
WO2018160967A1 (en) * 2017-03-02 2018-09-07 Board Of Regents, The University Of Texas System Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase
CN114181187A (zh) * 2021-11-24 2022-03-15 上海应用技术大学 一种4-甲磺酰胺基丁酰胺化合物的制备方法
WO2025155711A1 (en) * 2024-01-17 2025-07-24 The Board Of Trustees Of The Leland Stanford Junior University Lrrk2 inhibitors and compositions and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19815020A1 (de) * 1998-04-03 1999-10-07 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19816624A1 (de) 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
EP1212318A1 (de) 2002-06-12
ES2257313T3 (es) 2006-08-01
JP2003508394A (ja) 2003-03-04
CO5180641A1 (es) 2002-07-30
AU6998000A (en) 2001-03-26
CA2381821A1 (en) 2001-03-08
AR025389A1 (es) 2002-11-27
US6794395B1 (en) 2004-09-21
ATE316527T1 (de) 2006-02-15
EP1212318B1 (de) 2006-01-25
MXPA02002097A (es) 2002-11-07
DE50012136D1 (en) 2006-04-13
WO2001016130A1 (de) 2001-03-08
US20050009898A1 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
US6794395B1 (en) Substituted indolinones, their manufacture and their use as medicaments
US6762180B1 (en) Substituted indolines which inhibit receptor tyrosine kinases
KR100857734B1 (ko) 6위치가 치환된 인돌리논, 이를 포함하는 약제학적 조성물및 이의 제조방법
US7148249B2 (en) Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
JP2002525356A (ja) 新規置換インドリノン、それらの調製及び薬物としてのそれらの使用
US7160901B2 (en) Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
US6858641B2 (en) Substituted indolinones
JP2005533841A (ja) 6位で置換された、インドリノン誘導体、それらの調製及び薬物としてのそれらの使用
JP2004513113A (ja) 新規な置換インドリノン、その製造方法及びその医薬組成物としての使用
JP2005537276A (ja) 6−置換インドリノン誘導体、その製法及び医薬組成物としての使用
DE19940829A1 (de) Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE10029285A1 (de) Neue substituierte Indolinone,ihre Herstellung und ihre Verwendung als Arzneimittel

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20051107

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20051101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060207

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061023

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20061023

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20070409

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20070419

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees